Business Context and Reporting Period
This Form 8-K filing by Maiden Holdings, Ltd. (MHLD) covers events occurring between December 27, 2018, and January 3, 2019. The Company, a Bermuda-based holding company focused on reinsurance solutions, reported the completion of a significant asset disposition and the entry into a material definitive agreement to amend an existing reinsurance contract.
Key Financial Metrics and Transactions
- Asset Disposition: Completed the sale of Maiden Reinsurance North America, Inc. (MRNA) to Enstar Group Limited for net consideration of $272.4 million.
- Reinsurance Amendment: Entered a Partial Termination Endorsement with AmTrust Financial Services, Inc., resulting in the return of approximately $700.0 million in gross unearned premium (netting to approximately $480.0 million after ceding commission and brokerage).
- Pro Forma Impact (2017): Unaudited pro forma statements indicate that excluding the discontinued operations of MRNA, the Company would have reported a net loss attributable to common shareholders of $176.7 million for the year ended December 31, 2017, compared to a historical net loss of $199.1 million.
- Debt: The 7.75% Senior Notes due 2043 issued by Maiden Holdings North America, Ltd. remain outstanding following the disposition of MRNA.
Material Changes Versus Prior Period
The filing details a strategic shift involving the divestiture of the Company's U.S. treaty reinsurance business. The pro forma financial information adjusts historical results for 2015, 2016, and 2017 to reflect the sale of MRNA as if it occurred on January 1, 2015. This adjustment reclassifies the earnings of the sold subsidiary as discontinued operations, significantly altering the historical revenue and expense profiles presented in prior filings.
Guidance, Outlook, and Management Commentary
- Management Commentary: CEO Lawrence F. Metz stated that the amendment to the AmTrust quota share agreement "further strengthens Maiden's capital position while continuing to position Maiden for the future."
- Future Outlook: Management indicated that the remainder of the AmTrust Quota Share Agreement remains in-force and that the Company continues to work with AmTrust toward a potential new, smaller agreement.
- Contingencies: The $480 million return of unearned premium to AmTrust is subject to adjustment based on actual unearned premium calculations to be reported by May 30, 2019.
- Risks: The filing notes that pro forma financial statements do not necessarily reflect actual future results and may differ significantly due to various factors.
Important Facts for Investor Verification
- Verify the final closing adjustments for the MRNA sale to Enstar, as the $272.4 million figure is subject to post-closing adjustments.
- Monitor the reconciliation of the $480 million estimated unearned premium return to AmTrust, with final calculations due by May 30, 2019.
- Review the status of the 7.75% Senior Notes due 2043, which remain guaranteed by the Company despite the sale of the subsidiary that issued them.
- Confirm the terms of any potential new, smaller reinsurance agreement with AmTrust as management continues negotiations.